[结肠腺癌临床、形态学及分子生物学特征的预后价值]
[Prognostic values of the clinical, morphological and molecular biological characteristics of colon adenocarcinoma].
作者信息
Raskin G A, Pozharissky K M, Orlova R V, Petrov S V
机构信息
Russian Research Center for Radiology and Surgical Technologies, Saint Petersburg, Russia; Medical Faculty, Saint Petersburg State University, Saint Petersburg, Russia.
Russian Research Center for Radiology and Surgical Technologies, Saint Petersburg, Russia.
出版信息
Arkh Patol. 2015 Sep-Oct;77(5):26-30. doi: 10.17116/patol201577526-30.
OBJECTIVE
to estimate the predictive and prognostic factors using morphological studies in patients with colon cancer to increase survival rates.
SUBJECTS AND METHODS
Immunohistochemical examination was made in 582 patients with colon adenocarcinoma, by determining 11 different indicators relating to the development of the tumor and its treatment.
RESULTS
The simultaneous determination of the chemokine receptor CXCR4 and proliferative activity (Ki-67 expression) can define disease prognosis in view of relapse-survival rates in patients with Stage II colon cancer after radical surgical treatment.
CONCLUSION
Thymidylate synthase and thymidine phosphorylase are of predictive value. The immunohistochemical examination of other markers, such as ALDH1, CCR10, ERCC-1, DYPD, topoisomerase II alpha, and class III beta-tubulin for the choice of treatment policy for patients with colon cancer has indicated that they are of no value.
目的
通过对结肠癌患者进行形态学研究来评估预测和预后因素，以提高生存率。
对象与方法
对582例结肠腺癌患者进行免疫组织化学检查，测定与肿瘤发生发展及其治疗相关的11项不同指标。
结果
鉴于II期结肠癌患者根治性手术后的复发生存率，同时测定趋化因子受体CXCR4和增殖活性（Ki-67表达）可明确疾病预后。
结论
胸苷酸合成酶和胸苷磷酸化酶具有预测价值。对其他标志物（如ALDH1、CCR10、ERCC-1、DYPD、拓扑异构酶IIα和III类β微管蛋白）进行免疫组织化学检查以指导结肠癌患者的治疗策略选择，结果表明它们没有价值。
Zotero 插件